Coagulopathy associated with COVID-19

■ Coagulopathy associated with COVID-19

1 – About 20%-55% of patients admitted to hospital for coronavirus disease 2019 (COVID-19) have laboratory evidence of coagulopathy

2 – COVID-19-associated coagulopathy appears to be prothrombotic

3 – Elevated d-dimer concentration is associated with poor clinical outcomes

4 – In the absence of a contraindication, patients admitted to hospital should receive venous thromboembolism prophylaxis as per standard of care

5 – Transfusion of blood products should be avoided in patients who do not have active, major bleeding

■ Five things to know about: Coagulopathy associated with COVID-19

S G Lee, M Fralick, M Sholzberg

CMAJ 2020, VOL 192 (21): e583

■ Abnormal hemostatic parameters and risk of thromboembolism among patients with COVID-19 infection

R Castelli, A Gidaro

J Hematol 2020, vol 9 (1-2): 1-4

■ Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline

Z Ye, B Rochwerg, Y Wang et al

CMAJ 2020, vol 192 (20): E536-E545

■ Safety considerations with chroloquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

D N Juurlink

CMAJ 2020, vol 192 (17): E450-E453

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Estratificação de Risco Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Data: junho 2020